WO2005074605A3 - Produits moleculaires e recombinaison pour l'expression de l'oxygenase-1 hemique, l'oxygenase-2 hemique et/ou de la reductase biliverdine dans le traitement des maladies ou troubles neurodegeneratifs - Google Patents

Produits moleculaires e recombinaison pour l'expression de l'oxygenase-1 hemique, l'oxygenase-2 hemique et/ou de la reductase biliverdine dans le traitement des maladies ou troubles neurodegeneratifs Download PDF

Info

Publication number
WO2005074605A3
WO2005074605A3 PCT/US2005/003212 US2005003212W WO2005074605A3 WO 2005074605 A3 WO2005074605 A3 WO 2005074605A3 US 2005003212 W US2005003212 W US 2005003212W WO 2005074605 A3 WO2005074605 A3 WO 2005074605A3
Authority
WO
WIPO (PCT)
Prior art keywords
heme oxygenase
disorders
expression
treatment
neurodegenerative diseases
Prior art date
Application number
PCT/US2005/003212
Other languages
English (en)
Other versions
WO2005074605A2 (fr
Inventor
Mahin D Maines
Original Assignee
Univ Rochester
Mahin D Maines
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Rochester, Mahin D Maines filed Critical Univ Rochester
Publication of WO2005074605A2 publication Critical patent/WO2005074605A2/fr
Publication of WO2005074605A3 publication Critical patent/WO2005074605A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0083—Miscellaneous (1.14.99)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/001—Oxidoreductases (1.) acting on the CH-CH group of donors (1.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y103/00—Oxidoreductases acting on the CH-CH group of donors (1.3)
    • C12Y103/01—Oxidoreductases acting on the CH-CH group of donors (1.3) with NAD+ or NADP+ as acceptor (1.3.1)
    • C12Y103/01024—Biliverdin reductase (1.3.1.24)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/99—Miscellaneous (1.14.99)
    • C12Y114/99003—Heme oxygenase (1.14.99.3)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

L'invention porte sur des méthodes de traitement ou de prévention d'une maladie ou trouble neurodégénératif utilisant une thérapie génique ex vivo ou in vivo. La thérapie génique utilise un gène chimère un vecteur d'expression le contenant, le gène chimère comprenant une molécule d'ADN codant une protéine mammalienne sélectionnée dans le groupe de HO-1, HO-2 et BVR, et un promoteur, ce gène pouvant être exprimé dans des cellules neuronales couplé de manière fonctionnelle en 5' de la molécule d'ADN. Un autre procédé de traitement et de prévention d'une maladie ou trouble neurodégénératif consiste à administrer à un patient une protéine ou un polypeptide sélectionné parmi HO-1, HO-2 et BVR.
PCT/US2005/003212 2004-02-03 2005-02-03 Produits moleculaires e recombinaison pour l'expression de l'oxygenase-1 hemique, l'oxygenase-2 hemique et/ou de la reductase biliverdine dans le traitement des maladies ou troubles neurodegeneratifs WO2005074605A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54153004P 2004-02-03 2004-02-03
US60/541,530 2004-02-03

Publications (2)

Publication Number Publication Date
WO2005074605A2 WO2005074605A2 (fr) 2005-08-18
WO2005074605A3 true WO2005074605A3 (fr) 2006-05-26

Family

ID=34837499

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/003212 WO2005074605A2 (fr) 2004-02-03 2005-02-03 Produits moleculaires e recombinaison pour l'expression de l'oxygenase-1 hemique, l'oxygenase-2 hemique et/ou de la reductase biliverdine dans le traitement des maladies ou troubles neurodegeneratifs

Country Status (1)

Country Link
WO (1) WO2005074605A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2097094A4 (fr) * 2006-11-01 2011-01-05 George Mason Intellectual Prop Biomarqueurs pour etats neurologiques
EP2498825B1 (fr) 2009-11-09 2017-03-29 Genepod Therapeutics Ab NOUVEAU VECTEUR VIRAL POUR LA SYNTHESE DE DOPA CONTINUÉE ET & xA;SPECIFIQUE AUX NEURONES IN VIVO
KR101140391B1 (ko) * 2011-04-06 2012-05-03 강원대학교산학협력단 헴 옥시데이즈-1을 이용한 항비만 소재 탐색용 전구체 지방세포 개발 및 그 응용

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030050273A1 (en) * 2001-08-29 2003-03-13 Keiya Ozawa Compositions and methods for treating neurodegenerative diseases
WO2003055981A2 (fr) * 2001-12-21 2003-07-10 University Of Rochester Procedes de modulation de l'expression de la heme oxygenase-1 et de traitement des etats pathologiques medies par la heme oxygenase-1
US6793926B1 (en) * 1999-05-27 2004-09-21 Genovo, Inc. Methods for production of a recombinant adeno-associated virus

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6793926B1 (en) * 1999-05-27 2004-09-21 Genovo, Inc. Methods for production of a recombinant adeno-associated virus
US20030050273A1 (en) * 2001-08-29 2003-03-13 Keiya Ozawa Compositions and methods for treating neurodegenerative diseases
WO2003055981A2 (fr) * 2001-12-21 2003-07-10 University Of Rochester Procedes de modulation de l'expression de la heme oxygenase-1 et de traitement des etats pathologiques medies par la heme oxygenase-1

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HOEY J.G. ET AL: "Chimeric constructs containing the SH4/Unique domains of cYes can restrict the ability of Src527F to upregulate heme oxygenase-1 expression efficiently", CELLULAR SIGNALLING, vol. 12, no. 9-10, October 2000 (2000-10-01), pages 691 - 701, XP002995793 *
IMMENSCHUH S. ET AL: "Gene regulation of heme oxygenase-1 as a therapeutic target", BIOCHEM. PHARM., vol. 60, no. 8, 15 October 2000 (2000-10-15), pages 1121 - 1128, XP002995791 *
SABAAWY H.E. ET AL: "Human Heme oxygenase-1 gene transfer lowers blood pressure and promotes growth in spontaneously hypertensive rats", HYPERTENSION, vol. 38, no. 2, August 2001 (2001-08-01), pages 210, XP002995794 *
WANG X. ET AL: "Neotrofin increases Heme oxygenase-1 selectively in neurons", BRAIN RES., vol. 962, no. 1-2, 7 February 2003 (2003-02-07), pages 1 - 14, XP002995792 *

Also Published As

Publication number Publication date
WO2005074605A2 (fr) 2005-08-18

Similar Documents

Publication Publication Date Title
Katavetin et al. Antioxidative effects of erythropoietin
Griesenbach Progress and prospects: gene therapy clinical trials (part 2)
JP2023011696A (ja) 核酸産物およびその投与方法
IL296037A (en) Modulation of microbiota function by microbiome gene therapy to prevent, treat, or cure microbiome-related diseases or disorders
Onose et al. A review of published reports on neuroprotection in spinal cord injury
WO2005080581A3 (fr) Cassettes d'expression genique derivees d'herpesvirus etanches destinees a une expression genique soutenue et regulable
EP1455840A4 (fr) Traitement du cancer humain avec vector adenoviral tnf-alpha
BRPI0509278A (pt) polipeptìdeo isolado, molécula de ácido nucléico isolada, vetor, célula hospedeira isolada, linhagem de célula empacotadora, dispositivo celular biocompatìvel implantável, composição farmacêutica, uso do polipeptìdeo, ou da seqüência de ácido nucléico isolada, ou do vetor de expressão, ou de uma composição de células hospedeiras, ou de um dispositivo celular biocompatìvel implantável ou de uma linhagem de célula empacotadora, método de tratamento de uma condição patológica em um indivìduo, métodos para prevenir a apoptose em uma célula neuronal de mamìfero, para realçar a sobrevivência de uma célula neuronal de mamìfero, para gerar um neurÈnio, para expandir uma composição de células de mamìfero, e para diferenciar uma composição de células de mamìfero, anticorpo, e, imunoconjugado
Mottaghitalab et al. Prospects of siRNA applications in regenerative medicine
DE69635349D1 (de) Nukleotidsequenzen, proteine, medikamente und diagnoseagentien zur anwendung in krebsbehandlung
Dalise et al. Adaptive plasticity and recovery in preclinical models of stroke
WO2022076556A3 (fr) Administration thérapeutique de virus adéno-associé de protéine liée à la fukutine (fkrp) pour le traitement de troubles de la dystroglycanopathie comprenant des ceintures 2i (lgmd2i)
WO2002096195A8 (fr) Traitement ou therapie de remplacement faisant appel a des cellules souches transgeniques introduites dans l'intestin
Tang et al. Adenovirus-mediated delivery of GDNF ameliorates corticospinal neuronal atrophy and motor function deficits in rats with spinal cord injury
WO2005074605A3 (fr) Produits moleculaires e recombinaison pour l'expression de l'oxygenase-1 hemique, l'oxygenase-2 hemique et/ou de la reductase biliverdine dans le traitement des maladies ou troubles neurodegeneratifs
Isacson Models of repair mechanisms for future treatment modalities of Parkinson’s disease
Savino et al. A paradigm shift for erythropoietin: no longer a specialized growth factor, but rather an all-purpose tissue-protective agent
WO2002045737A3 (fr) Procedes de traitement mettant en application mda-7 humain
US20150111946A1 (en) Methods for delivery to the central nervous system of nucleic acid nanoparticles to treat central nervous system disorders
WO2009058970A3 (fr) Nouvelle méthode de thérapie génique concernant le traitement de l'obésité liée à des troubles du métabolisme
Bao et al. Drug-loaded zwitterion-based nanomotors for the treatment of spinal cord injury
Alton et al. Progress and prospects: gene therapy clinical trials (part 2)
WO2001081404A3 (fr) VECTEUR PLASMIDIQUE INDUCTIBLE CODANT TGF-ss, ET SES UTILISATIONS
WO2002101076A3 (fr) Procedes d'expression ciblee d'un acide nucleique therapeutique
Wang et al. Gene therapy of adeno‐associated virus (AAV) vectors in preclinical models of ischemic stroke

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase